Hanyu Pharmaceutical announced that the Liraglutide API from its wholly-owned subsidiary Hanyu Pharmaceutical Co., Ltd. has been approved and accepted by the Korea Food and Drug Administration. This drug is an analogue of human glucagon-like peptide-1 and has various physiological functions, including promoting insulin secretion in a glucose-dependent manner, protecting pancreatic beta cells, and delaying gastric emptying to reduce appetite. After future listing, it will enhance the company's competitiveness in the industry and is expected to have a positive effect on the company's future performance growth and industry position.

Hanyu Pharmaceutical announced that the Liraglutide API from its wholly-owned subsidiary Hanyu Pharmaceutical Co., Ltd. has been approved and accepted by the Korea Food and Drug Administration. This drug is an analogue of human glucagon-like peptide-1 and has various physiological functions, including promoting insulin secretion in a glucose-dependent manner, protecting pancreatic beta cells, and delaying gastric emptying to reduce appetite. After future listing, it will enhance the company's competitiveness in the industry and is expected to have a positive effect on the company's future performance growth and industry position.